Clinical Trials Browser

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02999633 2022-03-21

ISLAY

Phase 2 Terminated

14 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

69 enrolled 15 charts

Genitourinary

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00324467 2021-07-22

LYTPET

Phase 2 Unknown

150 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT00185692 2019-12-04

Allogeneic Transplantation From Related Haploidentical Donors

Phase 2 Completed

16 enrolled 8 charts

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Hodgkin Disease, Leukemia, Neoplasms, Hematologic Neoplasms

NCT02606994 2019-02-06

TPvsM

Phase 2 Terminated

1 enrolled

Other

Neoplasms, Stomatitis, Mucositis

NCT01332630 2018-09-20

TPI 287 in Breast Cancer Metastatic to the Brain

Phase 2 Completed

24 enrolled 8 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01985126 2018-06-25

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Phase 2 Completed

124 enrolled 18 charts

Plasma cell

Multiple Myeloma

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2 Terminated

3 enrolled 13 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Phase 2 Completed

36 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

NCT00899847 2017-10-20

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2 Completed

9 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT00490009 2017-03-30

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Phase 2 Completed

9 enrolled 10 charts

Lymphoid

Lymphoma

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Phase 2 Completed

68 enrolled 13 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00429702 2014-07-25

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Phase 2 Terminated

7 enrolled 6 charts

Nausea, Vomiting

NCT00515073 2014-07-03

Papillary Serous Carcinoma of the Endometrium

Phase 2 Completed

30 enrolled 5 charts

Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT00887640 2014-02-26

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Phase 2 Terminated

11 enrolled 9 charts

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00030992 2012-08-20

BMS 247550 to Treat Kidney Cancer

Phase 2 Completed

102 enrolled 10 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Clinical Trials

ADVANCE

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Iber-KDd

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

IZALCO

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

MK-3475-01C

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

OPTIMA-II

Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

versus

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

ISLAY

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

LYTPET

Allogeneic Transplantation From Related Haploidentical Donors

TPvsM

TPI 287 in Breast Cancer Metastatic to the Brain

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Papillary Serous Carcinoma of the Endometrium

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

BMS 247550 to Treat Kidney Cancer